

AD _____

GRANT NO: DAMD17-94-J-4129


TITLE: Identification of BRCA1 and 2 Other Tumor Suppressor Genes on
Chromosome 17 Through Positional Cloning

PRINCIPAL INVESTIGATOR: Dr. Raymond L. White

CONTRACTING ORGANIZATION: University of Utah
Salt Lake City, Utah 84112

REPORT DATE: 26 July 1995

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research and Materiel
Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950925 144

DTIC QUALITY INSPECTED 6

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 26 July 95		3. REPORT TYPE AND DATES COVERED Annual 1 Jul 94 - 30 Jun 95
4. TITLE AND SUBTITLE Identification of BRCA1 and 2 Other Tumor Suppressor Genes on Chromosome 17 Through Positional Cloning			5. FUNDING NUMBERS DAMD17-94-J-4129	
6. AUTHOR(S) Dr. Raymond L. White				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Utah Salt Lake City, Utah 84112			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) After the identification of BRCA1, it became evident that some breast and prostate tumors show allelic loss on chromosome 17q12-21 very close to, but not including, the BRCA1 locus. Therefore, we have analyzed two regions approximately 1Mb proximal and 1Mb distal to BRCA1, which show well defined loss of heterozygosity in sporadic breast tumors and sporadic prostate tumors respectively, to identify additional candidate tumor suppressor genes. Transcripts from these regions were identified using genomic reagents from our 4.5-Mb physical contig that contains the BRCA1 gene. Two novel members of the dlg2 and dlg3 disc-large family of genes, and a gene encoding an ADP-ribosylation factor (ARF4L) were identified in the distal region. In the proximal region we identified the plakoglobin gene, which previously had been thought to be located on chromosome 7. Plakoglobin, dlg2 and dlg3 are believed to be molecular components of cell-cell junctions, whereas ARF4L is believed to be involved in protein secretion and signal transduction. Several prominent tumor suppressor genes including the adenomatous polyposis coli gene (APC) and the Drosophila discs-large gene (Dlg) are components of cell-cell junctions, making three of the novel genes we identified and/or placed in the genomic region surrounding BRCA1 particularly interesting candidates for further investigation.				
14. SUBJECT TERMS BRCA			15. NUMBER OF PAGES 10	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to **stay within the lines** to meet **optical scanning requirements**.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

X Where copyrighted material is quoted, permission has been obtained to use such material.

X Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

X Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

X In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NTIS CRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

Roy White 7/26/95
PI - Signature Date

Table of contents

Front Cover	1
Report Documentation Page	2
Foreword	3
Table Of Contents	4
Introduction	5
Body	6-8
Conclusions	8
References	8-10
Appendix	10
Bibliography.....	10
List of Salaried Personnel.....	10

Introduction

The initial objective of this project were to identify a hereditary breast cancer gene, BRCA1, located on the long arm of chromosome 17, and two other tumor suppressor genes located near the extremities of chromosome 17. During the first three months of the grant period all our efforts were directed towards the characterization of candidates for BRCA1. The DNA sequences of several genes were obtained and analyzed for mutations during this effort to extend the development of our map of expressed sequences in the BRCA1 region (Albertsen et al., 1994). However, our emphasis on detecting BRCA1 changed after the appearance of two articles in Science (Miki et al. (1994), Futreal et al. (1994)) where a strong candidate gene for BRCA1 was presented. Evidence confirming that the candidate gene indeed is BRCA1 was subsequently found by several independent groups (Castilla et al.(1994), Friedman et al.(1994), Simard et al.(1994)). Based on these results, the first of the objectives in our proposal had been reached. However, with the exact location of BRCA1 known, it became evident that a narrowly delimited region of allelic loss could be detected less than 1Mb distal to BRCA1 in certain sporadic prostate tumors (Brothman et al. in press, Williams et al. submitted); 12 unrelated specimens showed narrow allelic losses distal to BRCA1, as observed either by LOH centered around D17S902 or by fluorescent in-situ hybridization using a collection of P1 clones isolated from a 400-1000kb region surrounding D17S902. Similarly, we and others reported a narrow region of loss of heterozygosity less than 1Mb proximal to BRCA1 in sporadic breast tumors (Cropp et al. 1994, Aberle et al. 1995); ten unrelated specimens showed LOH of a region with a minimal overlap of less than 120kb centered around D17S846. Because neither of these regions included the BRCA1 locus itself, the question was raised whether additional tumor suppressor genes were located in the immediate vicinity of BRCA1. Based on this observation and the observation that BRCA1 mutations have been identified in only a small fraction of sporadic breast tumors that show LOH on the long arm of chromosome 17 (Futreal et al., 1995), we concluded that the larger BRCA1 region (4.5Mb) was the likely home for additional tumor suppressor genes. Therefore, several of the expressed sequences we had identified in these two regions have been developed into full-length cDNA sequences and their predicted protein structure have been analyzed for recognizable domains and homologies. Of the four genes we identified, three are novel; the fourth gene, plakoglobin, has previously been extensively characterized for its biological function. However, its original genomic localization to chromosome 7 appears to have been based on a mis-

interpretation. Plakoglobin's true location on chromosome 17, its genomic structure and possible implication in tumorigenesis has been discussed (Aberle et al., 1995; Callahan et al. in preparation). Brief descriptions of each gene will be given below, followed by an appendix containing papers from our laboratory which have been accepted or submitted for publication.

Body

During the past twelve months several discoveries have been made with respect to breast cancer. Most significant was the discovery of Miki et al. (1994) and Futreal et al. (1994) of the BRCA1 gene itself; however, the genomic environment of BRCA1 has also revealed several interesting features. Dr. Solomon's group showed that the 5-prime end of BRCA1 is in very close proximity to the 5-prime end of the 1A1-3B gene (Brown et al., 1995), raising the possibility of studying transcriptional control (transcriptional dominance, positive or negative interference) among these two genes. Our group has found that the L21 riboprotein is located within the BRCA1 locus, in an intron flanking BRCA1 exon 14. We have made other potentially very interesting observations by analyzing primary tumors for allelic loss; those results have suggested the presence of two additional tumor suppressor genes in the immediate vicinity of BRCA1.

This new information placed us in a position where our resources were adequate to pursue either the physical mapping of the two distal tumor suppressor loci, as originally suggested in our grant proposal, or to identify the two potential tumor suppressor genes immediately flanking BRCA1 and located within our existing physical map of the BRCA1 region. Based on our knowledge that a physical map of the entire genome is under construction at the CEPH and that two proposals have been funded specifically to develop physical maps of chromosome 17, we realized that our original proposal to physically map the two distal tumor suppressor regions would be inefficient at best and possibly redundant. We decided to postpone our search for the two distal tumor suppressor genes for one or two years, until physical maps and genomic reagents from these regions become available from the other sources. Instead, we will concentrate our efforts on investigating the two potential tumor suppressor loci located next to BRCA1. Four possible candidate genes have been identified over the past 12 months: two *Drosophila* discs-large homologs, plakoglobin, and an ADP-ribosylation factor.

Protein components of cell-cell junctions.

Interaction among cells is critically important for maintaining proper cellular polarization and organization of the epithelial sheet. Generally described, intra-cellular orientation and inter-cellular communication and organization of epithelial cells are mediated via protein components of cell-cell junctions. Mutations in these protein components can lead to partial or complete loss of function of the cell-cell junctions, which would lead to misorganization of the tissue and subsequently to tumorigenesis. (For a literature review describing cell-cell junctions and their protein components see Kirkpatrick and Peifer 1995). On the basis of the predicted structure of two human Drosophila discs-large homologs we have identified in the BRCA1 region, *dlg2* and *dlg3*, we believe that the products of the genes, along with Plakoglobin, are protein components of cell-cell junctions.

Common to all members of the Drosophila discs-large family of genes are three distinct structural domains. At the N-terminal are 1-3 somewhat degenerate Drosophila homology regions (DHRs). DHR motifs are approximately 90 amino acids long and have been shown in vitro to bind cytoskeletal proteins of the band 4.1 family. A region with homology to src oncogene motif 3 (SH3) is found in the central part of the discs-large proteins. This motif, approximately 60 amino acids in length, is known to be a site of protein-protein interactions. Finally, a guanylate kinase domain (GK) is found at the C-termini of the Dlg proteins. The function of this domain is the catalytic transfer of phosphate from ATP to GMP, forming GDP. In Drosophila, Dlg has been shown to be a tumor suppressor (Woods et al., 1989).

Plakoglobin (also known as γ -catenin) contains several armadillo (Arm) repeats (Aberle et al., 1994). It is believed to interact directly with cadherins, α -catenin and the product of the APC gene (Su et al., 1993).

ADP-ribosylation factor (ARF4L) is, based on its predicted protein structure, believed to be involved in membrane trafficking and protein secretion. Six protein domains have been identified, three of which are involved with phosphate/magnesium binding, while the remaining three are involved with guanine nucleotide binding.

Genes from the critical regions.

Additional expressed sequences from the two regions in question exist, and if it becomes necessary to develop these reagents further it will be straightforward to do so. However, our

present focus is to characterize the four genes described above. We intend to do this in several ways, one of which will involve screening for mutations in these genes in sporadic tumors which reveal LOH. Alternatively, the genes will be tested for their biological roles in tissue culture systems, either through DNA oligo antisense-mediated suppression of normal gene expression or by transfecting breast epithelial cells with conditionally inducible expression vectors carrying the genes.

Conclusions

Although it was not our group that identified the BRCA1 gene, the past 12 months have been quite successful in our opinion. With respect to BRCA1, we developed and published the largest and most comprehensive physical map of the region and we are confident that it would have been a matter of short time before our strategy would have led us to the identification of BRCA1. With the precise localization of BRCA1 known, two narrow regions flanking BRCA1 on either side have emerged as candidate sites for additional tumor suppressor loci. We are presently investigating four genes from these regions for their possible roles as novel tumor suppressor genes.

References

- H. Aberle, S. Butz, J. Stappert, H. Weissing, R. Kemler and H. Hoschuetzky "Assembly of the cadherin-catenin complex in vitro with recombinant proteins". *Jour. Cell Sci.* **107**: 3655-3663 (1994).
- H. Aberle, C. Bierkamp, D. Torchard, O. Serova, T. Wagner, E. Natt, J. Wirsching, C. Heidkamper, M. Montagna, H.T. Lynch, G.M. Lenoir, G. Scherer, J. Feunteun and R. Kemler. "The human plakoglobin gene localizes to chromosome 17q21 and is subject to loss of heterozygosity in breast and ovarian cancers". *Proc. Natl. Acad. Sci. USA* **92**: 6384-6388.
- H.M. Albertsen, S.A. Smith, S. Mazoyer, E. Fujimoto, J. Stevens, B. Williams, P. Rodriguez, C.S. Cropp, P. Slijepcevic, M. Carlson, M. Robertson, P. Bradley, E. Lawrence, Z.M. Sheng, R. Hoopes, N. Sternberg, A. Brothman, R. Callahan, B.A.J. Ponder and R. White. "A physical map and candidate genes in the *BRCA1* region". *Nature Genetics* **7**: 472-479 (1994).
- A.R. Brothman, M.R. Steele, B.J. Williams, E. Jones, S. Odelberg, H.M. Albertsen, L.B. Jorde, L.R. Rohr and R. Stephenson. "Loss of chromosome 17 loci in prostate cancer detected by polymerase chain reaction quantitation of allelic markers". *Genes Chromosomes and Cancer* (In press) (1995).

M.A. Brown, K.A. Jones, H. Nicolai, M. Bonjardim, D. Black, R. McFarlane, P. de Jong, J. P. Quirk, H. Lehrach and E. Solomon. "Physical mapping, cloning, and identification of genes within a 500-kb region containing BRCA1". *Proc. Natl. Acad. Sci. USA* **92**: 4362-4366 (1995).

L.H. Castilla, F.J. Couch, M.R. Erdos, K.F. Hoskins, K. Calzone, J.E. Garber, J. Boyd, M.B. Lubin, M.L. Deshano, L.C. Brody, et al "Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer." *Nature Genetics* **8**: 387-91 (1994).

Craig S. Cropp, Z.-M. Sheng, H.A. Nevanlinna, H. Albertsen, R. White and R. Callahan "Genomic location and structure of plakoglobin". -*in preparation*.

C.S. Cropp, H.A. Nevanlinna, S. Pyrhönen, U.-H. Stenman, P. Salmikangas, H. Albertsen, R. White and R. Callahan. "Evidence for involvement of BRCA1 in sporadic breast carcinomas" *Cancer Research* **54**: 2548-2551 (1994).

L.S. Friedman, E.A. Ostermeyer, C.I. Szabo, P. Dowd, E.D. Lynch, S.E. Rowell and M.C. King. "Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families". *Nature Genetics* **8**: 399-404 (1994).

P.A. Futreal, Q. Liu, D. Shattuck-Eidens, C. Cochran, K. Harshman et al. "BRCA1 mutations in primary breast and ovarian carcinomas". *Science* **266**: 120-122 (1994).

C. Kirkpatrick and M. Peifer. "Not just glue: cell-cell junctions as cellular signaling centers". *Current Opinion in Genetics and Development* **5**: 56-65 (1995).

S.M. Mazoyer, S.A. Gayther, M.A. Nagai, S.A. Smith, A. Dunning, E.J. van Rensburg, H. Albertsen, R. White and B.A.J. Ponder. "A gene located at 17q12-21 encodes a new homologue of the Drosophila tumor-suppressor dlg-A protein" *Genomics* (in press) (1995).

Y. Miki, J. Swensen, D. Shattuck-Eidens, P.A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L.M. Bennett, W. Ding, et al. "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". *Science* **266**: 66-71 (1994).

J. Simard, P. Tonin, F. Durocher, K. Morgan, J. Rommens, S. Gingras, C. Samson, J.F. Leblanc, C. Belanger, F. Dion et-al "Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families". *Nature Genetics* **8**: 392-398 (1994).

S.A. Smith, P.R. Holik, J. Stevens, R. Melis, R. White and H. Albertsen. "Isolation and mapping of a gene encoding a novel human ADP-ribosylation factor on chromosome 17q12-q21." *Genomics* (in press) (1995).

S.A. Smith, P.R. Holik, J. Stevens, S. Mazoyer, R. Melis, B. Williams, R. White and H. Albertsen. "Isolation of a gene encoding a second member of the disc-large family on chromosome 17q12-21." *Genomics* (submitted) (1995).

L.K. Su, B. Vogelstein, K.W. Kinzler. "The APC tumor suppressor protein associates with catenins". *Science* **262**: 1734-1737 (1993).

B.J. Williams, E. Jones, X.J. Zhu, M.R. Steele, R.A. Stephenson, L.R. Rohr and A.R. Brothman. "Evidence for a tumor suppressor gene distal to BRCA1 prostate cancer." *Urology* (submitted) (1995).

D.F. Woods and P.J. Bryant. "Molecular cloning of the lethal (1) discs-large (1) oncogene of *Drosophila*". *Dev. Biol.* **134**: 222-235.

Appendix

- Bibliography (Publications resulting from the present grant)

S.A. Smith, P.R. Holik, J. Stevens, R. Melis, R. White and H. Albertsen. "Isolation and mapping of a gene encoding a novel human ADP-ribosylation factor on chromosome 17q12-q21." *Genomics* (in press) (1995).

S.M. Mazoyer, S.A. Gayther, M.A. Nagai, S.A. Smith, A. Dunning, E.J. van Rensburg, H. Albertsen, R. White and B.A.J. Ponder. "A gene located at 17q12-21 encodes a new homologue of the *Drosophila* tumor-suppressor dlG-A protein" *Genomics* (in press) (1995).

S.A. Smith, P.R. Holik, J. Stevens, S. Mazoyer, R. Melis, B. Williams, R. White and H. Albertsen. "Isolation of a gene encoding a second member of the disc-large family on chromosome 17q12-21." *Genomics* (submitted) (1995).

C.S. Cropp, Z.-M. Sheng, H.A. Nevanlinna, H. Albertsen, R. White and R. Callahan. "Plakoglobin: New mapping location and search for mutations in primary breast cancers" *Tumor Suppressor Genes, Baltimore*. (Meeting Abstract).

List of salaried personnel:

<u>Name:</u>	<u>Position:</u>	<u>Percent contribution to salary:</u>
Hans M. Albertsen,	Research Instructor,	67%
Jeff Stevens,	Research associate,	100%
Ray White,	P.I., Professor,	10%